Perrigo Co. PLC stock falls 2.79% and underperforms competitors

8 articles · Updated · MarketWatch · Apr 27

Perrigo shares closed at $11.49 on Monday, lagging behind rivals like Johnson & Johnson and Abbott Laboratories during a mixed market session.
The stock is now 59.59% below its 52-week high of $28.44, reached on July 25th, with trading volume at 2.8 million, below its 50-day average.
While the S&P 500 edged up and the Dow Jones dipped, Perrigo's decline outpaced sector peers, highlighting ongoing challenges for the company in a fluctuating market environment.

Down nearly 60% from its peak, is Perrigo stock a deep value play or a classic value trap?

As Perrigo restructures, which competitors are best positioned to seize its market share?

Why is Perrigo's Infant Formula business failing in a market projected to double in value?

Is Perrigo's high-yield dividend a confident promise or a risky gamble for investors?

Can a 7% workforce cut and new savings plan rescue Perrigo from its projected sales decline?